Clay Siegall: Strategically Positioning Seattle Genetics

The cancer research space is generally under-tapped with research into the disease and various treatment options still at the infancy stage. However, Seattle Genetics has joined the selected few companies that are already making a name for themselves and leaders in innovative targeted therapies for cancer developed intensive research. This unrivalled success has been achieved partly due to the incessant and impassioned dedication of the company’s cofounder and current chief executive office and board chairman, Clay Siegall. Backed by his Bachelor of Science degree in zoology and PhD in Genetics from the University of Maryland and George Washington University, respectively, Dr. Siegall has transformed Seattle Genetics into a colossal entity.

Clay Siegall has metamorphosed an idea that he first envisioned as a university student witnessing his close relative undergo through the excruciating pain of conventional cancer medications into a business entity with a global reputation. Even during challenging financial times, Dr. Siegall’s conviction in his dreams and the management capabilities of the company’s employees has always helped the company pull through and stay afloat. By strategically investing in research initiatives and embracing the concept of strategic partnerships, Clay Siegall’s Seattle Genetics has developed an FDA-approved cancer therapy drug, ADCetris. With partners such as Genentech, Pfizer and Bayer, Seattle Genetics to develop up to 20 new such drugs. If approved by FDA, the new additions will add to the company’s list of patents, which are its primary source of revenues.

Career History and Scholarly Achievements

Clay Siegall is an award-winning executive whose exploits at the head of Seattle Genetics saw him win the prestigious Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012. The honor was in recognition of his excellent track record including helping the company raise over $1.2 billion in capital to help with its cancer research and effective and innovative therapies. However, he holds that his experience between 1991 and 1997 while working at Bristol-Myers Squibb Pharmaceutical Research Institute was critical in his entrepreneurial success. Before founding Seattle Genetics in 1998, Clay Siegall also worked as a research scientist at National Cancer Institute up to 1991. He serves on board members of Ultragenyx Pharmaceutical among others. With up to 15 patents under his name and over 70 articles authored, Dr. Siegall is a dedicated oncology scholar.